Background: Sacubitril–valsartan has been shown to have superior effects over angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

The objective of this meta-analysis was to compare outcomes between sacubitril/valsartan
and enalapril in patients with heart failure. We performed this meta-analysis according to the …

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …

Abstract Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by
the international guidelines for the treatment of patients with chronic heart failure (HF) with …

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for
symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This …

Aims ARIADNE aimed to assess the association between effects of sacubitril/valsartan and
no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

Objectives: This paper aims to compare the effectiveness of sacubitril-valsartan and
angiotensin-converting enzyme inhibitor (ACE)/angiotensin receptor blocker (ARB) in …

Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older
patients with heart failure has not been explored. We aimed to investigate the risk of …

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …